Dimitriou, Nikolaos G.
Meuth, Sven G.
Martinez-Lapiscina, Elena H.
Albrecht, Philipp
Menge, Til http://orcid.org/0000-0003-3459-8867
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Article History
Accepted: 16 November 2022
First Online: 4 January 2023
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. There was no funding involved in the preparation of the manuscript.
: Nikolaos G. Dimitriou: no conflicts of interest to disclose. Sven G. Meuth: receives honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Healthcare, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS und Teva. His research is funded by the German Ministry for Education and Research (BMBF), Deutschen Forschungsgesellschaft (DFG), Else Kröner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Almirall, Amicus Therapeutics Germany, Biogen Idec, Diamed, Fresenius Medical Care, Genzyme, Merck Healthcare, Novartis, ONO Pharma, Roche, und Teva. Elena H Martinez-Lapiscina: no conflicts of interest to disclose. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties. Til Menge: personal fees from Biogen, BMS, Novartis, Teva, Roche, Merck Serono; non-financial support from Biogen, Merck Serono, Roche. Philipp Albrecht: received grants and non-financial support from Biogen; grants, personal fees and non-financial support from Allergan / Abbvie; personal fees and non-financial support from Bayer; personal fees and non-financial support from Sanofi Genzyme; grants, personal fees and non-financial support from Merck; grants, personal fees and non-financial support from Merz Pharmaceuticals; grants, personal fees and non-financial support from Novartis; grants, personal fees and non-financial support from Roche; grants, personal fees and non-financial support from Teva; and grants, personal fees and non-financial support from Ipsen, outside the submitted work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: NGD: first draft of manuscript and writing of manuscript. SGM: review and revision of the text. EHM-L: review and revision of the text. TM: first draft of manuscript and writing of manuscript. PA: First draft of manuscript and writing of manuscript. All authors have read and approve the final version of the manuscript, and agree to be accountable for the work.